Halozyme Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence.

CEO

Helen I. Torley

CEOHelen I. Torley

Employees

423

Employees423

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

423

Employees423

HALO Key Statistics

Market cap

12.58B

Market cap12.58B

Price-Earnings ratio

32.78

Price-Earnings ratio32.78

Dividend yield

—

Dividend yield—

Average volume

2.50M

Average volume2.50M

High today

$114.00

High today$114.00

Low today

$109.68

Low today$109.68

Open price

$111.62

Open price$111.62

Volume

2.14M

Volume2.14M

52 Week high

$116.85

52 Week high$116.85

52 Week low

$61.23

52 Week low$61.23

Stock Snapshot

With a market cap of 12.58B, Halozyme Therapeutics(HALO) trades at $110.79. The stock has a price-to-earnings ratio of 32.78.

As of 2026-10-07, Halozyme Therapeutics(HALO) stock has fluctuated between $109.68 and $114.00. The current price stands at $110.79, placing the stock +1.0% above today's low and -2.8% off the high.

The Halozyme Therapeutics(HALO)'s current trading volume is 2.14M, compared to an average daily volume of 2.5M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $116.85 and a 52-week low of $61.23.

HALO News

Simply Wall St 6h

Does Patent Injunction Win Change The Bull Case For Halozyme Therapeutics? - Simply Wall Street

...

TipRanks 12h

Halozyme announces Dutch court of the Hague found Merck infringed patents

Halozyme Therapeutics (HALO) announced that the specialized Dutch patent court of the Hague has found Merck (MRK) to be infringing one of its MDASE patents, EP...

TipRanks 1d

Halozyme expands global collaboration and license agreement with Argenx

Halozyme Therapeutics (HALO) announced that it has expanded its global collaboration and license agreement with Argenx (ARGX) to develop and commercialize ENHAN...

Analyst ratings

73%

of 11 ratings

Buy

72.7%

Hold

18.2%

Sell

9.1%

More HALO News

Simply Wall St 5d

Halozyme Therapeutics Brings Jim Daly Back To Its Board As Launch Focus Sharpens

Halozyme Therapeutics (NasdaqGS:HALO) has appointed veteran biopharma leader Jim Daly to its Board of Directors. Daly previously served on Halozyme's Board and...

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Kratos Defense & Security…

Micron Technology

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.